ICTM logo
Sarah Meredith FFPH, Deputy Director

Sarah is a clinical epidemiologist and public health physician with a particular interest in the safety and efficacy of medicines, and the design and conduct of studies to provide better evidence to support clinical and public health decisions about their use.

She joined the MRC Clinical Trials Unit in 2000 in the Division Without Portfolio.  She had the remit of supporting the development of clinical trials in areas in which there were important questions but a lack of necessary infrastructure or expertise to design, conduct or analyses the clinical trials needed to answer those questions.  As a result, she has collaborated on trials in a range of different clinical fields, particularly tuberculosis, dermatology (with the UK Dermatology Clinical Trials Network) and transfusion medicine (as part of the MRC/NHSBT Clinical Studies Unit).  Her current focus is improving the treatment and management of tuberculosis globally.

She previously worked at the National Heart and Lung Institute on respiratory disease surveillance, and in the Department of Preventive Medicine at Vanderbilt University where she developed an interest in pharmaco-epidemiology.

She has been the Deputy Director of the Unit since 2010.

Selected publications:

Ray WA, Murray KT, Meredith S, Narasimhulu S, Hall K, Stein M.  Erythromycin and the risk of sudden death from cardiac causes.  NEJM 2004; 351:1089-1096.

Ray WA, Taylor JA, Brown AK, Giddeon P, Hall K, Arbogast P, Meredith S.  Prevention of fall-related injuries in long-term care:  a randomized controlled trial of staff education.  Archives of Internal Medicine  2005; 165:2293-2298.

Elebute MO, Choo L, Mora A, Macrury C, Llewelyn C, Purohit S, Hicks V, Casey C, Malfroy M, Deary A, Reed T, Meredith S, Manson L, Williamson LM. Transfusion of prion-filtered red cells does not increase the rate of alloimmunization or transfusion reactions in patients: results of the UK trial of prion-filtered versus standard red cells in surgical patients (PRISM A). British Journal of Haematology. 2013 160; 5 701-708.

Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM , Chalmers JR, Nasr IS , Brindle RJ, English J, Meredith SK, Reynolds NJ, de Berker D, Mortimer PS and Williams HC on behalf of the UK Dermatology Clinical Trials Network’s PATCH I Trial Team. Penicillin to prevent leg cellulitis recurrence: randomized controlled trial; NEJM  2013 368;18 1695-1703.

Gillespie SG, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PPJ, Nunn AJ for the REMoxTB Consortium. Two Four-Month Moxifloxacin-based Regimens for Drug-Sensitive Tuberculosis. NEJM 2014 (in press).

Image of Sarah Meredith

Research interests:

  • Improvement of tuberculosis treatment and management
  • Support of clinical trials in underdeveloped areas
  • Risk-based approaches to clinical trial conduct

Research areas:

IRIS profile